Medivizor

Title of notification

Here comes the notification
X
 
icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: Arthritis Research & Therapy | Added Apr 03, 2022

Can filgotinib affect patient-reported outcomes and health-related quality of life in patients with rheumatoid arthritis?

This study investigated the effect of filgotinib (Jyseleca) on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) in patients that had active rheumatoid arthritis (RA). The study showed that filgotinib improved PROs in these patients and can be a treatment option for patients with insufficient responses to methotrexate (Otrexup; MTX), biological disease-modifying anti-rheumatic drugs (bDMARDs), and those that are MTX-naive (have never received MTX).

icon
rheumatoid arthritis | Research | 10 pages | source: Scientific reports | Added Oct 11, 2021

Do biologics increase the risk of blood clots in patients with rheumatoid arthritis?

This study looked at the risk of blood clots in patients with rheumatoid arthritis (RA) treated with biologics. It found that there was no significant increase in the risk of blood clots with biologics compared to other RA treatments.

icon
rheumatoid arthritis | Research | 10 pages | source: Annals of the rheumatic diseases | Added Oct 09, 2021

Is there a relationship between fatigue and disease activity in patients with early rheumatoid arthritis?

This study investigated the occurrence of fatigue (tiredness) in patients with early rheumatoid arthritis (RA) and identified predictors of fatigue after 24 months. The data showed that patients with early disease remission had a rapid, sustained reduction in fatigue and that low disease activity at diagnosis predicted a higher risk of fatigue at 24 months.

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: Arthritis Research & Therapy | Added Oct 05, 2021

Is peficitinib an effective treatment for rheumatoid arthritis?

This study looked at the use of peficitinib (Smyraf) for the treatment of rheumatoid arthritis (RA) from the perspective of patients and their doctors. It found that peficitinib improved symptoms of RA and led to increased ability to work and carry out daily activities compared to placebo.

icon
icon
rheumatoid arthritis | Research | Lifestyle | 10 pages | source: PLOS ONE | Added Sep 26, 2021

Can diet influence depression among patients with rheumatoid arthritis?

This study investigated the relationships among depression and anxiety, diet, and disease activity or physical function in patients with rheumatoid arthritis (RA). The data showed that there was a relationship between depression and lower fish intake frequency in these patients. 

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: Arthritis Research & Therapy | Added Jul 25, 2021

Is switching first-line targeted therapy for rheumatoid arthritis within 6 months of not reaching disease remission better than a traditional approach?

This study investigated whether switching a first-line targeted therapy (TT) within 6 months of not attaining low disease activity (LDA) enhances the chance of patients with rheumatoid arthritis (RA) achieving their target at the 12-month visit. The data showed an increased chance of achieving a target of remission or LDA at the 12-month visit with a TT switch within 6 months.

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: Arthritis Research & Therapy | Added Jul 11, 2021

Predicting the effectiveness of certolizumab pegol in rheumatoid arthritis by serum tumor necrosis factor alpha levels after 24 hours.

This study investigated the relationship between tumor necrosis factor-alpha (TNFα), interleukin (IL)-6, and serum certolizumab pegol (CZP; Cimzia) levels in patients with rheumatoid arthritis (RA) treated with CZP. The authors concluded that CZP was highly effective in patients with low serum TNFα levels at 24 hours after the first dose.

icon
rheumatoid arthritis | Research | 10 pages | source: European review for medical and pharmacological sciences | Added Jun 30, 2021

Do biological DMARDs affect fracture risk in patients with rheumatoid arthritis?

This study analyzed the effect of using biological disease-modifying anti-rheumatic drugs (bDMARDs) on fracture risk in patients with rheumatoid arthritis (RA). The data suggest no evidence that the use of bDMARDs impacts fracture risk in these patients.

icon
rheumatoid arthritis | Research | 10 pages | source: The Journal of Rheumatology | Added Jun 13, 2021

Can COVID-19 vaccines be used in patients with autoimmune rheumatic diseases?

This study described the guidelines from the Canadian Rheumatology Association (CRA) on the use of COVID-19 vaccines in patients with autoimmune rheumatic diseases (ARDs). The CRA recommended the use of Canada-approved COVID-19 vaccines for patients with ARDs.

icon
icon
rheumatoid arthritis | Research | Lifestyle | 10 pages | source: Medicine | Added May 23, 2021

How effective are resistance exercises in rheumatoid arthritis treatment?

This study reviewed the effectiveness of resistance exercise in patients with rheumatoid arthritis (RA). The data showed that resistance exercise can significantly improve disease activity in these patients.

View

Category

  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon

Was this helpful?